Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial

expresspharmaMarch 11, 2021

Tag: Lilly , Bamlanivimab , Etesevimab , COVID-19 , BLAZE-1

PharmaSources Customer Service